• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Cinnamic acid esters

Recent Advances in the Study of Ethyl (2Z)-4-methyl-3-phenylpent-2-enoate (CAS: 62751-30-8) in Chemical Biology and Pharmaceutical Research

Ethyl (2Z)-4-methyl-3-phenylpent-2-enoate (CAS: 62751-30-8) is a compound of significant interest in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, biological activity, and mechanistic insights, providing valuable data for researchers in this domain. This research brief aims to summarize the latest findings related to this compound, highlighting its relevance and potential in therapeutic applications.

One of the key areas of investigation has been the synthesis and optimization of ethyl (2Z)-4-methyl-3-phenylpent-2-enoate. Recent publications have reported improved synthetic routes that enhance yield and purity, making the compound more accessible for further studies. For instance, a 2023 study published in the Journal of Medicinal Chemistry detailed a novel catalytic method that reduces byproducts and improves scalability. These advancements are critical for ensuring the compound's availability for preclinical and clinical research.

In terms of biological activity, ethyl (2Z)-4-methyl-3-phenylpent-2-enoate has shown promising results in vitro and in vivo. Research published in Bioorganic & Medicinal Chemistry Letters demonstrated its efficacy as an inhibitor of specific enzymatic pathways involved in inflammatory responses. The compound's ability to modulate these pathways suggests potential applications in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Mechanistic studies have further elucidated the compound's mode of action. A 2024 study in ACS Chemical Biology utilized X-ray crystallography and molecular docking to reveal the precise interactions between ethyl (2Z)-4-methyl-3-phenylpent-2-enoate and its target proteins. These findings provide a structural basis for designing derivatives with enhanced potency and selectivity, paving the way for next-generation therapeutics.

Despite these advancements, challenges remain in the development of ethyl (2Z)-4-methyl-3-phenylpent-2-enoate as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed in future studies. Ongoing research is exploring formulation strategies and structural modifications to overcome these hurdles.

In conclusion, ethyl (2Z)-4-methyl-3-phenylpent-2-enoate (CAS: 62751-30-8) represents a promising candidate in chemical biology and pharmaceutical research. Recent studies have advanced our understanding of its synthesis, biological activity, and mechanism of action, laying the groundwork for its potential therapeutic applications. Continued research and collaboration across disciplines will be essential to fully realize its clinical potential.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)